Angiotensin II-HIF-1α Axis Suppresses Ferroptosis in NPC Radioresistance

Study Background and Research Question

Radiotherapy remains the primary curative modality for nasopharyngeal carcinoma (NPC), an epithelial malignancy with high prevalence in East and Southeast Asia. Despite technological advances, approximately 20% of NPC patients experience local recurrence or residual disease following radiotherapy, a challenge largely attributed to the emergence of radioresistant tumor cell populations. Understanding the molecular mechanisms underlying this radioresistance is crucial for identifying effective radiosensitizing agents and improving treatment outcomes. Recent evidence implicates the local renin-angiotensin system (RAS), specifically angiotensin II (Ang II), in promoting tumor progression and therapy resistance within the tumor microenvironment. However, the precise mechanisms by which Ang II modulates NPC radioresistance, particularly in the context of ferroptosis—a form of regulated cell death characterized by iron-dependent lipid peroxidation—remained unclear prior to the current study.

Key Innovation from the Reference Study

The reference study (Chengcong Chen et al., 2025) delivers a mechanistic breakthrough by demonstrating that local Ang II promotes radioresistance in NPC by suppressing ferroptosis through the HIF-1α-HILPDA axis. The authors establish that Ang II creates a positive feedback loop with hypoxia-inducible factor-1 alpha (HIF-1α) via two converging mechanisms: activation of the MAPK pathway to stabilize HIF-1α, and direct binding of angiotensinogen (AGT) to HIF-1α to prevent its degradation. This loop transcriptionally upregulates hypoxia-inducible lipid droplet-associated protein (HILPDA), enhancing lipid droplet accumulation and thereby reducing susceptibility to ferroptosis. The study further provides evidence that targeting Ang II signaling—combined with ferroptosis induction—can markedly increase radiosensitivity in NPC models.

Methods and Experimental Design Insights

To dissect the role of local Ang II in NPC radioresistance, the researchers employed a robust suite of molecular and cellular techniques:

• Establishment of radioresistant NPC cell lines (HONE1-RR and SUNE1-RR) via repeated irradiation cycles.
• Quantitative reverse transcription PCR (qRT-PCR), western blot, and ELISA to assess AGT and Ang II levels, as well as downstream effectors HIF-1α, HILPDA, and GPX4.
• Transmission electron microscopy, ferrous ion quantification, and lipid peroxidation assays to evaluate radiation-induced ferroptosis.
• Bioinformatics analyses and dual-luciferase reporter assays to elucidate transcriptional regulation mechanisms.
• Colony formation and Cell Counting Kit-8 (CCK-8) assays to measure radiosensitivity in vitro.
• Nude mouse xenograft models to validate findings in vivo.
• Immunohistochemistry on patient-derived NPC tissues to correlate AGT, HIF-1α, HILPDA, and GPX4 expression with clinical radiosensitivity and prognosis.

The integration of molecular profiling, functional assays, and in vivo validation provides a comprehensive framework for understanding the AGT-HIF-1α-HILPDA axis in NPC radioresistance.

Core Findings and Why They Matter

The study's central findings are as follows:

• Local Ang II suppresses ferroptosis in NPC cells by activating the HIF-1α-HILPDA axis. This suppression is mediated both through MAPK pathway-dependent stabilization and direct interaction between AGT and HIF-1α.
• HILPDA transcriptionally promotes lipid droplet accumulation, which inhibits lipid peroxidation and ferroptotic cell death, thereby promoting radioresistance.
• Combined treatment with Ang II receptor blockers (ARBs) and ferroptosis inducers significantly enhances NPC radiosensitivity, suggesting a synergistic therapeutic strategy.
• Expression levels of AGT, HIF-1α, and HILPDA in patient samples are closely associated with ferroptosis intensity, radiosensitivity, and clinical prognosis.

These results advance the understanding of how the tumor microenvironment modulates radiotherapy response. By clarifying the role of the AGT-HIF-1α-HILPDA pathway in suppressing ferroptosis, the study identifies new biomarkers and actionable targets for overcoming radioresistance in NPC.

Protocol Parameters

• Radioresistant cell line establishment: Subject NPC cells to repeated fractionated irradiation until stable radioresistance is confirmed by colony formation and viability assays.
• Ferroptosis assessment: Measure lipid ROS and ferrous ion accumulation post-irradiation; use transmission electron microscopy for morphological confirmation.
• Pharmacological intervention: Apply clinically relevant concentrations of ARBs and established ferroptosis inducers; optimize timing relative to irradiation.
• In vivo validation: Utilize nude mouse xenograft models to assess tumor volume reduction and histological markers of ferroptosis following combinatorial treatments.
• Correlative biomarker analysis: Perform immunohistochemical staining for AGT, HIF-1α, HILPDA, and GPX4 on patient-derived tissue microarrays; correlate with radiotherapy outcomes.

Comparison with Existing Internal Articles

Several recent internal reviews corroborate the mechanistic insights provided by this study. For example, "Angiotensin II-HIF-1α Axis Drives Radioresistance in NPC" and "Angiotensin II Drives Radioresistance via HIF-1α-HILPDA in NPC" both highlight the central role of Ang II in NPC radioresistance and propose dual targeting of the Ang II/HIF-1α axis and ferroptosis pathways. These articles further contextualize the importance of the MAPK pathway in mediating these effects, aligning closely with the reference study's findings. Additionally, the internal article "SCH772984: ERK1/2 Inhibitor Workflow Optimization in Tumor Models" provides practical protocols for dissecting MAPK/ERK pathway involvement in radioresistance and ferroptosis. These resources collectively strengthen the translational relevance of targeting the AGT-HIF-1α-HILPDA axis in preclinical and clinical settings.

Limitations and Transferability

While the study leverages rigorous in vitro and in vivo approaches, several limitations should be noted:

• The radioresistant models were established in specific NPC cell lines, and findings may not fully extrapolate to the broader molecular heterogeneity of patient tumors.
• Although the study uses immunohistochemistry to correlate biomarker expression with clinical outcomes, prospective validation in larger, independent patient cohorts is necessary.
• The combinatorial efficacy of ARBs and ferroptosis inducers was demonstrated in preclinical models; clinical translation will require further pharmacodynamic and safety evaluation.

Nevertheless, the mechanistic insights into Ang II-mediated suppression of ferroptosis via the HIF-1α-HILPDA axis provide a robust foundation for further translational research targeting radioresistance in NPC.

Research Support Resources

For researchers aiming to interrogate the MAPK/ERK pathway's role in tumor radioresistance and ferroptosis, selective inhibitors offer essential experimental precision. SCH772984 (SKU A3805) is a potent and selective ATP-competitive ERK1/2 inhibitor that enables targeted MAPK/ERK pathway inhibition in cell-based and in vivo models. Leveraging such inhibitors can facilitate mechanistic dissection of downstream signaling, including the impact on ferroptosis and radioresistance, as highlighted in the referenced and internal studies. APExBIO provides detailed usage protocols and storage recommendations to support robust experimental design.